Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

392.76 -3.36 (-0.85%)
Streaming Delayed Price Updated: 12:32 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
65 66 Next >
These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend
These winners seem likely to keep up their winning ways. 
Via The Motley Fool
Topics Stocks
A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts
 
Via Benzinga
Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings
 
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today
 
Via Benzinga
Is Vertex Pharmaceuticals Stock a Buy Now?
The biotech's prospects keep improving. 
Via The Motley Fool
Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture?
 
Via Benzinga
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
With a new medicine on the market and plenty of money, Vertex is in great shape. 
Via The Motley Fool
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
The Ultimate Growth Stock to Buy With $1,000 Right Now
The stock, trading for about $60, has plenty of room to run. 
Via The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in January
Start the year off right by investing in these quality businesses. 
Via The Motley Fool
Investing Trends to Follow in 2024
We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors
Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent. 
Via InvestorPlace
Will the Biotech sector sustain its momentum in 2024?
The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%. 
Via MarketBeat
Topics ETFs
The Best Stocks to Invest $1,000 in Right Now
It's not too late to get in on these market beaters. 
Via The Motley Fool
Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics
CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead. 
Via The Motley Fool
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High
Via Investor Brand Network
January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway.
These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly. 
Via The Motley Fool
Topics Stocks
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
Prediction: These 3 Stocks Will Soar in 2024
Investors could enjoy an especially happy new year with these great stocks. 
Via The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade.
These stocks offer attractive risk-reward profiles. 
Via The Motley Fool
2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now
It's been a crazy year across sectors, but winners remain. 
Via The Motley Fool
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.